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Abstract. There is currently intense controversy regarding the use of hormone replacement therapy (HRT) in postmenopausal
women, in relation to its therapeutic efﬁcacy in Alzheimer’s disease (AD). It has been suggested that the beneﬁts of HRT may be
modiﬁed by apolipoprotein E (APOE) genotype (the major genetic risk factor for AD). Here we report the ﬁndings of the ﬁrst
study designed to systematically explore the interaction of (a) oestrogen replacement therapy (ERT) and (b) possession of an ε4
allele of APOE on speciﬁc elements of episodic learning and memory that are commonly used indices of age-related cognitive
decline. This data represents a cross-sectional analysis of the interaction of ERT and APOE genotype on learning and memory in
a cohort of 181 healthy postmenopausal women [ERT users (n = 101, mean age 65.40 ± 6.34); ERT non-users (n =8 0 , mean
age 67.03 ± 6.80)] residing in Perth, Western Australia. The highest level of learning (trials 2–5; P<0.05) and memory (e.g.
total number of items recalled; P<0.05) performance was observed in women taking ERT who were not carriers of the APOE
ε4 allele. APOE ε4 carriers receiving ERT performed no better on episodic memory testing than APOE ε4 carriers who were
not receiving ERT. These cognitive differences related to genetic proﬁle, were noted on both recall and recognition (P =0 .005)
tests of memory. The ﬁndings have signiﬁcance for evaluating whether and when ERT may be clinically indicated. Speciﬁcally,
ERT may beneﬁt the cognitive functioning of women not carrying the APOE ε4 allele.
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1. Introduction
The use of hormone replacement therapy (HRT)
in postmenopausal women is currently highly contro-
versial, in particular with regard to the possibly in-
creased incidence of breast cancer and cardiovascular
disease [1]. In addition, there has been some sug-
gestion that combined oestrogen-progesterone therapy
may actually increase the risk of Alzheimer’s disease
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if initiated at age 65 or older [2]. This paper reports
the ﬁrst study to systematically evaluate the effects on
episodiclearningandmemoryofunopposed-oestrogen
replacementtherapy(ERT)inwomeneitherpossessing
orlackingtheε4 allele ofthe apolipoproteinE (APOE)
gene. APOE ε4 is thought to predispose individuals
to the incidence of Alzheimer’s disease (AD) [3–5].
Perhaps independently, APOE ε4 may be an impor-
tant factor in modulating normal age-related cognitive
change[6]. Furthermore,APOEε4hasbeensuggested
to confer a higher risk for AD in women (in whom
there is a higher overall incidence of AD) compared to
men [7–9].
A decrease in endogenous oestrogen levels after
menopause has been proposed as a trigger for the de-
velopment of AD in women [10,11]. A signiﬁcant
body of evidence suggests that HRT administered to
postmenopausalwomenmaypreventordelaytheonset
of AD [11,12] but neither treats nor reverses the dis-
ease [13,14]. In recent years researchers have there-
fore directed their attention towards evaluating the role
of oestrogen in delaying and/or preventing the onset
of age-related cognitive decline. Improvements have
previously been observed following oestrogen supple-
mentation in healthy postmenopausal women on tests
of episodic learning and memory [15,16], and in some
women with mild AD [17]. Interestingly, it has been
suggested that the therapeutic efﬁcacy of HRT is mod-
iﬁed by APOE genotype [18,19]. Speciﬁcally, carriers
of the ε4 allele do not seem to beneﬁt from receiving
oestrogen [19]. However, the possible interaction of
ERT onepisodic memoryperformancein those with or
withoutan APOE ε4 allele has not yet been thoroughly
investigated. This was the central goal of this study.
We evaluated episodic verbal learning and memory, as
deﬁcits in these cognitive domains are apparent in the
very early stages of AD [20].
2. Materials and methods
2.1. Participants
A total of 181 cognitively healthy Caucasian post-
menopausalwomenweretested. Participantswerecur-
rently enrolled in a longitudinal study on the effects of
different forms of HRT on cognitive ageing (assessed
via global measures of cognition) at the Sir James Mc-
Cusker Alzheimer’s Disease Research Unit at the Uni-
versity of Western Australia, Perth, Western Australia.
To achieve the goal of this study, (a) a fresh selection
criteria (outlined in detail below) was placed on the
participants of the longitudinal study, to yield a subset
consisting only of unopposed oestrogen takers (i.e. no
progestin, either independently or in conjunction with
oestrogen) and (b) to this subset a neuropsychological
assessmenttesting thecognitivedomainofinterest (i.e.
episodiclearningandmemory)hadto be administered.
Participant information relating to medical history,
useofERT andrecentperformanceontheMiniMental
Status Exam (MMSE) [21] and the Cambridge Exam-
ination for Mental Disorders in the Elderly- Cognitive
Section (CAMCOG) [22] was available. Participants
were selected for the study if they met the following
criteria: (a) score > 24 on the MMSE and (b) score >
80 on the CAMCOG. Taken together, criteria (a) and
(b) excludedindividuals with dementia from the study.
The application of these criteria therefore excluded in-
dividuals with frank cognitive deﬁcits. In addition, (c)
individuals with medical history of stroke, minor head
injuries (e.g. concussion) and/or functional psychiatric
disorders(e.g.clinical depression)were excludedfrom
the study and (d) participants were further selected for
the study on the basis of whether they were currently
taking unopposed ERT. Speciﬁcally, participants were
selected for the study if they were receiving one stan-
dardclinical dose of oestrogen(i.e. 0.625mg Premarin
or equivalent), and (e) if they had been taking ERT
for more than 12 months. The rationale for employing
these selection criteria (d) and (e) were as follows; (i)
to negate dose to dose variability and in turn standard-
ize dosages of different forms of ERT (i.e. Premarin,
Ogen, Progynova, Transdermal Oestrogen and Oestra-
diol),and(ii)byexcludinguseunder12months,partic-
ipantsincludedin this study were takingERT fora suf-
ﬁcient duration for it to have therapeutic efﬁcacy. The
literature suggests that the efﬁcacy of ERT in delaying
the onset of preclinical cognitive decline and AD is
both dose and durationdependent[9]. Finally, (f) indi-
viduals with no prior history of ERT use were selected
as control participants [control participants underwent
the same exclusioncriteria (a) to (c) noted above]. De-
mographic characteristics of the cohort are presented
broken down by ERT and APOE status, respectively
(Tables 1 and 2).
This study was conducted in accordance with the
guidelines of local institutional human research ethics
committees (University of Western Australia and Mur-
doch University) and informed consent was obtained
from all participants.M.S. Burkhardt et al. / Oestrogen replacement therapy may improve memory functioning 223
Table 1
Demographic Characteristics of the Cohort
ERT users (n =1 0 1 ) ERT Non-users (n =8 0 )
Mean SD Range Mean SD Range
Age (years) 65.40 ±6.34 50–78 67.03 ±6.80 54–80
Educationa 12.68 ±2.74 8–22 12.43 ±3.11 9–24
Baseline MMSEb 28.85 ±1.35 25–30 28.98 ±1.16 25–30
Baseline CAMCOGc 99.49 ±4.17 85–106 99.36 ±3.86 88–107
Note. aValues represent total years of education (years of schooling + years of higher
education).
bMaximum possible score = 30.
cMaximum possible score = 107.
Table 2
Demographic Characteristics of the Cohort
ε4+ (n =6 4 ) ε4− (n =1 1 7 )
Mean SD Range Mean SD Range
Age (years) 66.86 ±6.63 52–79 65.71 ±6.54 50–80
Educationa 12.16 ±2.96 8–22 12.79 ±2.86 9–24
Baseline MMSEb 28.69 ±1.34 25–30 29.03 ±1.21 25–30
Baseline CAMCOGc 99.13 ±4.61 85–107 99.60 ±3.68 89–106
Note. ε4+, possession of an APOE ε4 allele; ε4−, absence of the APOE ε4 allele.
aValuesrepresenttotalyearsofeducation(yearsofschooling+yearsofhighereducation).
bMaximum possible score = 30.
cMaximum possible score = 107.
2.2. Neuropsychological assessment
Learning and memory of verbal information was
assessed by administration of the California Ver-
bal Learning Test (CVLT) [23], a multidimensional
neuropsychological instrument that assesses episodic
learning and memory (i.e. immediate and delayed re-
call and delayed recognition) within the context of
an everyday memory task (i.e. remembering a word
list). There is a 20-minute memory interval on the
CVLT, after which delayed memory performance (re-
callandrecognition)isevaluated. Duringthisdelay,the
Beckdepressioninventorysecondedition(BDI-II)[24]
was administered to participants (this score was ob-
tainedduetotheknowncorrelationbetweencurrentde-
pressive symptomatology and cognitive performance,
whichmaybeespeciallyrelevantintheelderly). Blood
was also taken duringthe CVLT memorydelay using a
standard venipuncture technique.
2.3. APOE genotyping
Peripheral blood leukocyte DNA was extracted us-
ing standard protocols [25]. APOE genotyping was
performed via PCR ampliﬁcation as described previ-
ously [26]. The oligonucleotide primers were used
as described elsewhere [27]. The ampliﬁed prod-
uct was digested using the restriction enzyme HhaI
(Fisher Biotech, Perth, Australia), followed by visual-
ization under UV light to reveal DNA fragments with
electrophoretic migration patterns unique to each al-
lele [27].
3. Results
In this study the 4 groups of participants that were
tested are represented by the following nomenclature:
E+ and E− refer to whether or not participants in
that group were receiving ERT at the time of testing,
whereas ε4+ and ε4− refer to whether participants in
that group were carrying an ε4 allele.
3.1. Descriptive statistics
Duetothemannerinwhichthesamplewas recruited
there were a higher proportion of individuals carrying
the ε4 allele than would be expected in the general
population. However, there is no difference in the fre-
quency of the ε4 allele between the E+ and E− groups
(Pearson’s χ2 value = 0.05, P =0 .82). As such,
any effect that this selection bias may have had would
be expected to be consistent between the groups and
thus negated. Additionally, the E+ and E− groups did
not differ with respect to the following: demographic
variables (i.e. age, educational level), overall cognitive224 M.S. Burkhardt et al. / Oestrogen replacement therapy may improve memory functioning
Fig. 1. Learning across the ﬁve CVLT trials as a function of participant group status. Error bars represent standard error of the mean. E + and
E− refer to whether or not participants in that group were receiving ERT at the time of testing. ε4 + and ε4− refer to whether participants in that
group were carrying an ε4 allele. Note that there was no statistically signiﬁcant difference between performances of the four groups on the ﬁrst
learning trial, but signiﬁcant differences had emerged by the second trial.
status (i.e. score on the CAMCOG and on the MMSE)
(Table 1) depression scores on the BDI-II, and family
history of AD.
The ε4+ and ε4− groups did not differ with respect
to demographic variables, overall cognitive status (Ta-
ble 2) or depression scores. The use of ERT in the ε4+
and ε4− group was similar. However, as anticipated,
a family history of AD was signiﬁcantly higher in in-
dividuals identiﬁed as possessing the APOE ε4 allele
compared to the non-carriers (Pearson’s χ2 value =
4.60, P =0 .03).
From the results of the cognitive assessment that
was administered to participants, the following vari-
ables were highly correlated with all of the learning
and memory parameters that were assessed: (a) age
andscores on(b)the CAMCOG andon (c)the MMSE.
These variables (a), (b) and (c) were therefore used as
covariatesinthestatisticalanalysesofthememorydata
that are reported below.
The learning and memory data are summarized in
the next paragraph, and then presented in more detail
in subsequent paragraphs.
3.2. Learning and memory data
Bettercognitiveperformanceacrossthelearningand
memory trials was observed with ERT treatment in in-
dividuals who were not carrying the APOE ε4 allele,
but not in individuals who were carrying the ε4 allele,
with the E+/ε4− group performing best overall. This
effect was apparent on both recall memory and recog-
nition memory. These overall ﬁndings are presented in
more detail below (Fig. 1 and Table 3).
3.2.1. Learning
A 2-way (4 × 5: group × learning trial) ANCOVA
indicated that there was a trend towards a signiﬁcant
differencein the level of performancebetween the four
participant groups when the recall data were collapsed
across learning trials 1–5, F (3,174) = 2.13, P =0 .10.
This difference was statistically signiﬁcant when the
datawerecollapsedacrosslearningtrials2–5,F(3,174)
= 2.72, P<0.05. Pairwise comparisons showed the
E+/ε4− group performed best overall, with the overall
performance of the other 3 groups indicating that they
were not different from each other statistically.M.S. Burkhardt et al. / Oestrogen replacement therapy may improve memory functioning 225
Table 3
Group means ±SD for selected CVLT scores
ERT users ERT non-users
ε4+ (n =3 5 ) ε4− (n =6 6 ) ε4+ (n =2 9 ) ε4− (n =5 1 ) P value
List A Trial 1 6.94(±2.57) 7.30(± 2.08) 6.76(± 2.57) 6.96(± 2.02) 0.82
List A Trial 5 11.91(± 3.22) 13.18(± 2.25) 12.62(± 2.64) 12.02(± 2.68) 0.03
T r i a l5–T rial 1 4.97(± 2.29) 5.88(± 2.34) 5.86(± 2.40) 5.06(± 2.75) 0.03
Σ Trial 1 to 5 49.91(± 13.19) 55.48(± 9.59) 50.86(± 11.52) 50.51(± 9.76) 0.08
SDFR 10.29(± 3.92) 11.83(± 2.55) 10.72(± 3.14) 10.39(± 3.12) 0.06
SDCR 11.69(± 3.37) 12.83(± 2.17) 12.03(± 3.03) 11.89(± 2.10) 0.14
LDFR 10.63(± 3.65) 12.27(± 2.65) 11.10(± 3.60) 11.22(± 2.78) 0.11
LDCR 11.51(± 3.53) 13.15(± 2.10) 11.90(± 3.38) 12.31(± 2.15) 0.15
Forgetting index:
SDFR – LDFR 0.34(± 1.89) 0.44(± 1.52) 0.38(± 1.63) 0.82(± 2.59) 0.57
Trial5 – LDFR −1.29(± 2.48) −0.91(± 1.93) −1.52(± 2.85) −0.80(± 2.65) 0.66
Recognition:
Hits 14.83(± 1.54) 15.15(± 1.10) 14.41(± 1.68) 14.51(± 155) 0.61
False Positivesa 1.54(± 2.15) 0.52(± 0.90) 1.14(± 1.57) 1.02(± 1.36) 0.05
DI 93.77(± 6.10) 96.94(± 3.20) 93.81(± 6.01) 94.30(± 4.39) 0.07
Note. ε4+, possession of an APOE ε4 allele; ε4−, absence of the APOE ε4 allele; SDFR, short delay free
recall; SDCR, short delay cued recall; LDFR, long delay free recall; LDCR, long delay cued recall; DI,
discriminability index.
aLow scores signify better performance.
3.2.2. Recall
Recall measures evaluated the ability to reproduce
items presented on the original CVLT word list, either
in free recall or in response to a category cue (cued
recall).
3.2.2.1. Memory – Delayed recall
On the ability to recall after a few minutes’ delay,
1-way ANCOVA (4 levels of the factor group) showed
that there was a trend for a signiﬁcant effect of group
status to emerge on long delay cued recall, F (3,174)
= 2.26, P =0 .08. Comparisons indicated that the
pattern of performance across the four groups was as
noted across the learning trials, with the E+/ε4− group
performingatthehighestlevel. Similarpatternsofdata
were revealedwhenthe short and longdelay free recall
and the short delayed cued recall data were analysed.
Importantly, a signiﬁcant inter-group difference was
most robustly observed between the E+/ε4− and the
E+/ε4+ participants.
3.2.2.2. Memory – Total recall
Total recall performance was evaluated using 1-way
ANCOVA (4 levels of the factor group) by calculating
the sum of recall performance across the ﬁve learning
trials and four delayed trials. When this analysis was
conducted, there was a similar pattern of data as previ-
ously noted across the 4 participant groups (F (3,174)
= 2.50, P =0 .06).
Another statistical procedure was undertaken using
the total recall measure: the data were ﬁltered so that
the effects of ERT could be evaluated separately in
those individuals either possessing or not possessing
the ε4 allele. When only the data from the ε4− par-
ticipants was analysed using 1-way ANCOVA, there
was a statistically signiﬁcant effect of ERT on episodic
memory performance (F (1,112) = 7.36, P<0.01).
However, no such effects of treatment were present if
ERTwasevaluatedonlyinthoseindividualspossessing
the ε4 allele. These ﬁndings were also indicated when
the full data set was evaluated: using 2-way (2 × 2:
group × treatment) ANCOVA, there was a signiﬁcant
interaction between the factor of ERT status and the
factorof ε4 status on the total numberof items recalled
(F (1,173) = 6.03, P<0.05).
3.2.3. Recognition
3.2.3.1 Discriminability index (DI)
Thisindexofrecognitionmemoryperformancemea-
sures the ability to discriminate words on the target
memory list from words on a similar interference list,
andfromdistractorsthat werenotpresentoneitherlist.
1-way ANCOVA (4 levels of the factor group) showed
that there was a signiﬁcant difference between groups
on the level of performance on the DI, F (3,174) =
4.41, P =0 .005. The pattern of performance across
the 4 groups was similar to that previously noted with
respect to the memory recall data: post hoc testing in-
dicated signiﬁcantly better performancein the E+/ε4−
group compared with the 3 other participant groups.
This group difference was indicated both in terms of
thenumberofhit andfalse positiveresponsesthatwere226 M.S. Burkhardt et al. / Oestrogen replacement therapy may improve memory functioning
made (hits: F (3,173) = 2.19, P =0 .09; false posi-
tives: F (3,173) = 3.31, P<0.05).
3.2.3.2. Response bias
This index of recognition performance measures an
individual’s tendency to respond “yes” to any item
(whether correct or incorrect) on “yes”/“no” recogni-
tion. Performance on this measure did not differ sig-
niﬁcantly between the four participant groups.
Further statistical analyses were conducted in order
to evaluate all the ﬁndings reported above when par-
ticipants scoring either the maximum level of learning
and memory performance (“ceiling”) or the minimum
level of learning and memory performance (“ﬂoor”)
were excluded from the analyses. When this was un-
dertaken, the ﬁndings were very similar to those that
have already been reported by us here.
4. Discussion
This is the ﬁrst clinical study in the literature to
explore systematically the interaction between oestro-
gen administration and APOE genotype on speciﬁc
elements of learning and memory in healthy post-
menopausalwomen. Improvementsrelative to age and
education-matched controls have previously been ob-
served following oestrogen supplementation in post-
menopausal women on tests of learning and mem-
ory [14,15]. However, the interaction of this phe-
nomenonwiththeAPOEε4allelehasnotyetbeenthor-
oughly investigated. The study revealed that, within
a modestly sized cohort of postmenopausal women,
speciﬁc components of episodic learning and memory
were affected by ERT and genetic status. More specif-
ically, oestrogen and APOE ε4 status impacted upon
verbal episodic memory, with the best memory perfor-
mance being observed in women receiving ERT who
were APOE ε4 negative.
Ofinterest,furtherinspectionofthememorydatain-
dicated that the most marked group difference was ob-
served between the E+/ε4− and E+/ε4+ participants.
Furthermore, when the total recall data were evaluated
as a composite measure of episodic memory, it was
apparent that only individuals who were ε4− beneﬁted
from ERT. This point is further emphasized by the ob-
servation that, on the vast majority of memory indices,
the ε4+ group who received ERT performed no better
than the E−/ε4− group. Taken together, these are po-
tentially very important ﬁndings, indicating that ERT
may not be able to compensate for the deleterious ef-
fects of the APOE ε4 allele on memory. This ﬁnd-
ing requires further investigation, as it has substantial
health implications. In particular, if there are indeed
other health risks associated with ERT (such as en-
hanced risk of breast cancer, cardiovascular disease or
thromboembolic disease), then ERT prescribed for its
potential cognitive beneﬁts may be contra-indicated in
individuals who possess the APOE ε4 allele.
A further important point concerns the relationship
betweenthelearningandmemorydata. Thereisaclose
relationship in all individuals between the ability to
learn and the ability to remember, such that the former
clearly affects the latter. What is striking about the
data obtained in the current study is that, when one
takes into account statistically the group differences in
memoryperformancethathaddevelopedbythetimeof
the ﬁfth learning trial, then the observed differences in
delayed recall performance across the four groups are
rendered non-signiﬁcant (for reasons of conciseness,
theseanalysesarenotpresentedintheprevioussection;
further details are available upon request). The data
obtained in this study therefore indicate that memory
differencesbetweengroups(basedontheirERT andε4
status) are established within a few learning trials, and
these differencesarethen maintainedacross the groups
in terms of delayed memory performance.
Inaddition,whenconsideringthelearningandmem-
orydatareportedinthisstudy,itshouldbenotedthatin-
dividual differences in performance on the CAMCOG
andMMSEwerecontrolledforwithintheanalysesthat
wereconducted. Itshouldbenotedthatthis produceda
somewhat conservative analysis of the episodic mem-
orydata, giventhatboththeCAMCOG andtheMMSE
contain certain elements that are related to episodic
memory functioning. This consideration renders the
group-related differences in learning and memory per-
formance that we report here all the more striking.
In a related study, Yaffe et al. [19] recently found
thatovera72-monthperiod,ε4carriersmanifestedless
of an HRT treatment effect, in that they had a faster
rate of cognitive decline compared to those not pos-
sessing the ε4 allele. Nevertheless, in the study re-
ported by Yaffe et al. [19], HRT still seemed to beneﬁt
the ε4 carriers when cognitive performance was com-
pared to the ε4 carriers who were not receiving oestro-
gen [19]. Our ﬁndings contrast with those of Yaffe et
al. [19], in that, in our study, ε4 carriers did not beneﬁt
from the administration of HRT, whereas those indi-
viduals who were ε4 negative did. In another recent
study conducted by Hays et al. [28], it was reported
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did not beneﬁt mental health or cognitive status in a
large sample of postmenopausal women. However, in
the study reported by Hays et al. [28], cognitive status
was evaluated using a non-speciﬁc instrument derived
from the MMSE. This considerationalso applies to the
recent study reported by Shumaker et al. [2], which
used a similarly non-speciﬁc cognitive instrument. By
contrast, in the present study we evaluated those spe-
ciﬁc elements of verbal episodic memory, which are
knownto be most sensitive to age-relatedcognitivede-
cline. With respect to the discrepancies noted between
the ﬁndings of this study and the ﬁndings of Yaffe et
al. [19], Hays et al. [28] and Shumaker et al. [2], our
ﬁndings therefore indicate that the speciﬁc elements of
cognitionthatarebeingevaluatedinlargescale clinical
trials should be carefully considered before embark-
ing on research studies with serious and wide-ranging
implications. This is an especially pertinent point in
the context of those several studies that have used brief
cognitive instruments such as the MMSE. The MMSE
is a clinical instrument that is quick to administer, and
which is very widely used, but which offers little de-
tailed iformation and has limited cognitive speciﬁcity.
Another possible explanation for apparent discrep-
ancies in the literature relates to the speciﬁcity, dose
and temporal characteristics of the HRT that was eval-
uated in this study. For example, in this study unop-
posedERTwasinvestigated,asdistinctfromcombined
oestrogen-progesterone therapy, which has been eval-
uated in most previous studies. The contrasting effects
of ERT that were observed in the ε4+ and ε4− partici-
pantsinthisstudydonot,however,seemtoberelatedto
inadequate statistical power due to the smaller number
of participants in the ε4+ group. When the ε4− group
was randomly reduced in size to make it comparable
to the ε4+ group, signiﬁcant effects of ERT were still
observed in the ε4− group but not in the ε4+ group.
(For reasons of space, these results are not reported in
this paper, but are available upon request).
The possible interaction of ERT on memory perfor-
mance in those with or without the APOE ε4 allele has
notbeen properlyinvestigatedin the past. This was the
central aim of our study. We evaluated verbal learning
and memory, as deﬁcits in these cognitive domains are
apparent in the very early stages of AD, and these el-
ements of cognition have been used as sensitive mark-
ers of age-related cognitive decline. Our ﬁndings indi-
catethat ERT maybea usefulprophylacticapproachto
age-related cognitive decline and AD in certain post-
menopausalwomen,butitsneuroprotectiveactionmay
be substantially modiﬁed by possession of the APOE
ε4 allele. Given the potential health risks associated
with the use of some forms of ERT, the ﬁndings of this
paper are of considerablesigniﬁcance in allowing clin-
icians and patients to make more informed decisions
regarding the prescribing of ERT in postmenopausal
women.
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